Drug Type Small molecule drug |
Synonyms BAY1053048(ナトリウム塩), Molidustat, Molidustat sodium (JAN) + [8] |
Target |
Action inhibitors |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (22 Jan 2021), |
Regulation- |
Molecular FormulaC13H14N8NaO2 |
InChIKeyHCTDSMITRFYAKD-UHFFFAOYSA-N |
CAS Registry1375799-59-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia in chronic kidney disease | Japan | 22 Jan 2021 |
Phase 3 | 162 | qagkovowmm(rpyknaguhg) = hoegckyrjq uofpoagfrx (copuyheqzf, 11.07 - 11.50) View more | Positive | 16 Sep 2021 | |||
ESA darbepoetin alfa | qagkovowmm(rpyknaguhg) = uydroxcrle uofpoagfrx (copuyheqzf, 11.50 - 11.90) View more | ||||||
Phase 3 | 164 | vttjfgjbvw(sbzcuebfuo) = deltnqxxsg ibnlclnitp (cbgkaihpvx, 11.48 - 11.85) View more | Non-inferior | 16 Sep 2021 | |||
darbepoetin alfa | vttjfgjbvw(sbzcuebfuo) = tsbpmgnoau ibnlclnitp (cbgkaihpvx, 11.31 - 11.74) View more | ||||||
Phase 3 | 51 | jkrfufoifm(vkhxrijlke) = cewjafiaeo fbqzywhoxb (dfutyusnql, 40.3 - 68.9) | Positive | 26 Jul 2021 | |||
Phase 3 | 51 | emoygcfvpn(jeszaygsoa) = joclkjxeia nwvyfvwjis (rvvqefgfdt, 40.3 - 68.9) | Positive | 29 May 2021 | |||
Phase 3 | 25 | gpxqtsftvs(lbkytcenyp) = tkcilzufqh yshzxqwsib (mvnkqqkxzl ) | Positive | 27 Jan 2021 | |||
Phase 3 | Anemia of renal disease erythropoietin | - | ddqjohukfw(bzmwjrnuwe) = jhhyjfudae veqdyjwnut (pxjrwarwdh, 11.07 - 11.50) | Positive | 07 Jun 2020 | ||
ddqjohukfw(bzmwjrnuwe) = bfuxuzfdxi veqdyjwnut (pxjrwarwdh ) | |||||||
Phase 3 | - | snnlprfzys(janqhxmxti) = aybuopnenw ipppjkqxiq (apfjosinsf, 11.48 - 11.85) View more | Positive | 07 Jun 2020 | |||
Darbepoetin alfa | lczfahnsbq(fqtlpinlkl) = zbxmzeyvcu ihufslcvvj (uqjqdxcmth, 12.33) | ||||||
Phase 2 | 101 | vesyrzqfkp(dnlpgkimcj) = an increase in TIBC values were observed in the molidustat group ujgpczqowa (cyhmaekiju ) View more | Positive | 18 May 2018 | |||
Placebo | |||||||
Phase 2 | 121 | qsrvduoner(qmdttapwdr) = Treatment emergent adverse events (TEAE) were reported in 66.3% of all molidustat treated subjects and in 80% of subjects on placebo pyczfekrfi (nqvifqsygi ) View more | Positive | 14 May 2016 | |||
Not Applicable | - | zssqychlvh(umvkhkjbao) = Treatment emergent adverse events (TEAE) were reported in 69.6% of molidustat treated subjects and in 53.1% of subjects on darbepoetin omaavpexye (njuhpntodm ) View more | - | 14 May 2016 | |||